

30th December, 2025

To,

The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. Scrip Code: 539523	National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai 400 051. Scrip Symbol: ALKEM
---	--

Sub: Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (“SEBI LODR Regulations”)- Update on transfer of the trade generics business of the Company

Dear Sir(s)/Madam,

This is in continuation of our earlier intimations dated 10th December, 2024, and 26th September, 2025, wherein the Stock Exchanges were informed about the transfer of the trade generics business of M/s. Alkem Laboratories Limited (“the Company”) as a going concern, on a slump sale basis, to M/s. Alkem Wellness Limited, a wholly owned subsidiary of the Company incorporated in India (“Alkem Wellness”), effected through a Business Transfer Agreement effective from 1st October, 2025.

In this regard, we wish to inform you that today, i.e., 30th December, 2025, the balance sale consideration of Rs. 32.5 crores has been paid by Alkem Wellness to the Company, aggregating to a final sale consideration of Rs. 532.5 crores, pursuant to the terms and conditions of the Business Transfer Agreement dated 26th September, 2025.

The above information is also available on the website of the Company at www.alkemlabs.com.

Kindly take the same on your records.

Sincerely,
For **Alkem Laboratories Limited**

Manish Narang
President – Legal, Company Secretary & Compliance Officer